Oric Pharmaceuticals Inc is a biotechnology business based in the US. Oric Pharmaceuticals Inc shares (ORIC) are listed on the NASDAQ and all prices are listed in US Dollars. Oric Pharmaceuticals Inc employs 107 staff and has a market cap (total outstanding shares value) of 0.00.
Paid non-client promotion. Finder does not invest money with providers on this page. If a brand is a referral partner, we're paid when you click or tap through to, open an account with or provide your contact information to the provider. Partnerships are not a recommendation for you to invest with any one company. Learn more about how we make money.
Finder is not an advisor or brokerage service. Information on this page is for educational purposes only and not a recommendation to invest with any one company, trade specific stocks or fund specific investments. All editorial opinions are our own.
| Latest market close | $10.07 |
|---|---|
| 52-week range | $5.27 - $16.65 |
| 50-day moving average | $9.42 |
| 200-day moving average | $9.91 |
| Wall St. target price | $18.57 |
| PE ratio | N/A |
| Dividend yield | N/A (0%) |
| Earnings per share (TTM) | $-1.76 |
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Historical closes compared with the close of $10.07 from 2024-09-03
| 1 week (2024-08-29) | -1.27% |
|---|---|
| 1 month (2024-08-05) | 13.53% |
| 3 months (2024-06-05) | 9.81% |
| 6 months (2024-03-05) | -34.99% |
| 1 year (2023-09-05) | 11.89% |
|---|---|
| 2 years (2022-09-02) | 186.89% |
| 3 years (2021-09-03) | 23 |
| 5 years (2019-09-01) | N/A |
| Gross profit TTM | $0 |
|---|---|
| Return on assets TTM | -25.2% |
| Return on equity TTM | -38.79% |
| Profit margin | 0% |
| Book value | $4.47 |
| Market Capitalization | $731.5 million |
TTM: trailing 12 months
We're not expecting Oric Pharmaceuticals Inc to pay a dividend over the next 12 months.
Over the last 12 months, Oric Pharmaceuticals Inc's shares have ranged in value from as little as $5.27 up to $16.65. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Oric Pharmaceuticals Inc's is 1.117. This would suggest that Oric Pharmaceuticals Inc's shares are a little bit more volatile than the average for this exchange and represent, relatively-speaking, a slightly higher risk (but potentially also market-beating returns).
ORIC Pharmaceuticals, Inc. , a clinical-stage biopharmaceutical company, engages in the discovery and development of therapies for treatment of cancers in the United States. Its clinical stage product candidates include ORIC-114, a brain penetrant orally bioavailable irreversible inhibitor, currently under Phase 1b study, which is designed to selectively target epidermal growth factor receptor and human epidermal growth factor receptor 2 with high potency towards exon 20 insertion mutations; ORIC-944, an allosteric inhibitor of the polycomb repressive complex 2 for prostate cancer, currently under Phase 1b study; and ORIC-533, an orally bioavailable small molecule inhibitor of CD73, currently under Phase 1b study, being developed for resistance to chemotherapy- and immunotherapy-based treatment regimens. The company is also developing multiple discovery stage precision medicines targeting other cancer resistance mechanisms, including ORIC-613, an orally bioavailable, highly selective inhibitor of PLK4, in preclinical studies for the treatment of breast cancers. It has a license and collaboration agreement with Voronoi Inc. ; a license agreement with Mirati Therapeutics, Inc. ; and clinical development collaboration agreement with Pfizer Inc.
Use this calculator to quickly see potential outcomes of your options trades.
SoFi, Robinhood, Tastytrade, Webull, Interactive Brokers, E*TRADE, eToro and others top our list for the best options trading platforms.
A covered call is an options trading strategy that allows you to generate income from stocks you already own.
A look at GSD Capital’s highlights, limitations, fees and investment strategies.
Explore the best bonuses for opening a new brokerage account.
Looking for a discount broker like E*TRADE that offers something different? Here are some of the top alternatives to consider.
Charles Schwab and Fidelity are two powerhouse trading platforms for beginner and advanced investors.
Interactive Brokers has advanced charting tools but a high net requirement to qualify.
Discover the top tech stocks poised to lead innovation and offer substantial growth opportunities.
Learn about Wealthfront’s automated investing tools and services to see if it’s the right platform for you.